Valuation dashboard for Neurogene Inc. (NGNE) with P/E N/A, P/B 3.58, EV/EBITDA -4.69 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $34.67, NGNE has negative trailing earnings (P/E not meaningful) and an ROE of -45.11%. Market capitalisation stands at $548M.
Balance sheet quality for NGNE: current ratio of 16.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.58 |
| EV / EBITDA | -4.69 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $4.36 |
| vs Current Price | -87.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NGNE | Neurogene Inc. | $548M | 3.58 | -45.1% | |
| PRTC | PureTech Health plc | $4.2B | 0.13 | -31.8% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% |
Price
| Price | $34.67 |
| Market Cap | $548M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -45.11% |
| Return on Invested Capital | -53.72% |
| Return on Assets | -45.47% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADCT · ALMS · AUTL · BNTC · FULC · LCTX · OCGN
Explore sector: Healthcare · Biotechnology
More sections of NGNE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks